SEC Form 4
SpyGlass Pharma, Inc. (SGP) insider trading
In the 12 months to Oct 26, 2026, 15 SGP insiders reported open-market purchases of $221.5M across 16 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $221.5M
- 16 filings
Who traded SGP, and when
- Purchase
SGP daily close from Feb 6, 2026 to Oct 26, 2026, between $17.56 and $30.03, last $30.03. 0 sale and 16 purchase filings by 15 insiders, marked at their filing dates. Rajeev M. Shah, Director: bought $55.1M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Ali Behbahani, Director: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Anthony A. Florence JR., 10% owner: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Carmen Chang, 10% owner: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Edward T. Mathers, 10% owner: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Forest Baskett, 10% owner: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Mohamad Makhzoumi, 10% owner: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. NEA Partners 17, L.P., 10% owner: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Paul Edward Walker, 10% owner: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Rick Yang, 10% owner: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Scott D. Sandell, 10% owner: bought $15.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Kirk G. Nielsen, Director → 10% owner: bought $5.3M across 2 filings, first filed Feb 10, 2026, last Feb 10, 2026. Geoffrey B. Pardo, Director: bought $5.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Peter Kolchinsky, Director: bought $4.0M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Bilal Arshad Khan, Director: bought $2.2M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026.
Largest mark · tap a row for others
Rajeev M. Shah · Director
Purchase $55,071,456
3,441,966 shares at $16.00 avg
Filed Feb 11, 2026 · traded Feb 9
Close on filing date $27.55
Rajeev M. Shah · Director
Director
$55.1M boughtAli Behbahani · Director
Director
$15.0M boughtAnthony A. Florence JR. · 10% owner
10% owner
$15.0M boughtCarmen Chang · 10% owner
10% owner
$15.0M boughtEdward T. Mathers · 10% owner
10% owner
$15.0M boughtForest Baskett · 10% owner
10% owner
$15.0M boughtMohamad Makhzoumi · 10% owner
10% owner
$15.0M boughtNEA Partners 17, L.P. · 10% owner
10% owner
$15.0M boughtPaul Edward Walker · 10% owner
10% owner
$15.0M boughtRick Yang · 10% owner
10% owner
$15.0M boughtScott D. Sandell · 10% owner
10% owner
$15.0M boughtKirk G. Nielsen · Director → 10% owner
Director → 10% owner
$5.3M boughtGeoffrey B. Pardo · Director
Director
$5.0M boughtPeter Kolchinsky · Director
Director
$4.0M boughtBilal Arshad Khan · Director
Director
$2.2M boughtOpen-market trades
16 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Rajeev M. Shah | Director | — | $55.1M | 1 | — | |
| Ali Behbahani | Director | — | $15.0M | 1 | — | |
| Anthony A. Florence JR. | 10% owner | — | $15.0M | 1 | — | |
| Carmen Chang | 10% owner | — | $15.0M | 1 | — | |
| Edward T. Mathers | 10% owner | — | $15.0M | 1 | — | |
| Forest Baskett | 10% owner | — | $15.0M | 1 | — | |
| Mohamad Makhzoumi | 10% owner | — | $15.0M | 1 | — | |
| NEA Partners 17, L.P. | 10% owner | — | $15.0M | 1 | — | |
| Paul Edward Walker | 10% owner | — | $15.0M | 1 | — | |
| Rick Yang | 10% owner | — | $15.0M | 1 | — | |
| Scott D. Sandell | 10% owner | — | $15.0M | 1 | — | |
| Kirk G. Nielsen | Director → 10% owner | — | $5.3M | 2 | — | |
| Geoffrey B. Pardo | Director | — | $5.0M | 1 | — | |
| Peter Kolchinsky | Director | — | $4.0M | 1 | — | |
| Bilal Arshad Khan | Director | — | $2.2M | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Paul Edward Walker 10% owner | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | Carmen Chang 10% owner | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | Edward T. Mathers 10% owner | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | Scott D. Sandell 10% owner | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | Mohamad Makhzoumi 10% owner | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | Rick Yang 10% owner | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | NEA Partners 17, L.P. 10% owner | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | Forest Baskett 10% owner | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | Anthony A. Florence JR. 10% owner | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | Ali Behbahani Director | Purchase | 937,500 | $16.00 | $15.0M | 6,035,038 | |
traded | Peter Kolchinsky Director | Purchase | 248,034 | $16.00 | $4.0M | 2,054,678 | |
traded | Rajeev M. Shah Director | Purchase | 3,441,966 | $16.00 | $55.1M | 5,966,439 | |
traded | Geoffrey B. Pardo Director | Purchase | 312,500 | $16.00 | $5.0M | 2,187,513 | |
traded | Bilal Arshad Khan Director | Purchase | 135,000 | $16.00 | $2.2M | Multiple accounts | |
traded | Kirk G. Nielsen 10% owner | Purchase | 165,000 | $16.00 | $2.6M | 3,310,619 | |
traded | Kirk G. Nielsen Director | Purchase | 165,000 | $16.00 | $2.6M | 3,310,619 |
GET /stocks/filings/vX/form-4?tickers=SGP&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"SGP"
],
"issuer_cik": "0001778922",
"owner_cik": "0001384859",
"accession_number": "0001231919-26-000135",
"form_type": "4",
"filing_date": "2026-02-11",
"period_of_report": "2026-02-09",
"issuer_name": "SpyGlass Pharma, Inc.",
"issuer_trading_symbol": "SGP",
"owner_name": "Kolchinsky Peter",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-02-09",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 248034,
"transaction_price_per_share": 16,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 2054678,
"transaction_value": 3968544,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnotes",
"footnotes": [
{
"id": "F2",
"description": "RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."
},
{
"id": "F4",
"description": "Held directly by the Nexus Fund III."
}
],
"remarks": "Dr. Zachary Scheiner, a Principal of the Adviser, serves on the Issuer's board of directors."
},
{
"tickers": [
"SGP"
],
"issuer_cik": "0001778922",
"owner_cik": "0001346824",
"accession_number": "0001231919-26-000135",
"form_type": "4",
"filing_date": "2026-02-11",
"period_of_report": "2026-02-09",
"issuer_name": "SpyGlass Pharma, Inc.",
"issuer_trading_symbol": "SGP",
"owner_name": "RA CAPITAL MANAGEMENT, L.P.",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-02-09",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 3441966,
"transaction_price_per_share": 16,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 5966439,
"transaction_value": 55071456,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnotes",
"footnotes": [
{
"id": "F2",
"description": "RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."
},
{
"id": "F3",
"description": "Held directly by the Fund."
}
],
"remarks": "Dr. Zachary Scheiner, a Principal of the Adviser, serves on the Issuer's board of directors."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 65 records
- Other65 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has SpyGlass Pharma, Inc.'s CEO sold stock?
No. Patrick H. Mooney (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is SGP’s insider data?
These are SGP Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track SGP insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for SGP every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.